---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-012376"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2025-04-18T23:59:59+00:00"
generated_at: "2026-05-23T11:23:07.341388+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Windtree Therapeutics director Craig Fraser resigns from board

## Summary
- Craig Fraser resigned from the Board effective April 17, 2025.
- Resignation was not due to any disagreement with management or company operations.
- Board reduced from five to four members following Fraser's departure.
- Fraser was not a member of any Board committees.

## SEC filing metadata
- accession: 0001437749-25-012376
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2025-04-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774925012376/0001437749-25-012376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774925012376/wint20250418_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-012376
- JSON: https://secwatch.observer/filing/0001437749-25-012376.json
- Plain text: https://secwatch.observer/filing/0001437749-25-012376.txt

## Key facts
- Executive change
  Craig Fraser resigned as Director at WINDTREE THERAPEUTICS INC /DE/.
  - Action: resigned
  - Role: Director
  source text: On April 17, 2025, Mr. Fraser notified the Windtree Therapeutics, Inc.(the “ Company ”) Board of Directors (the “ Board ”) of his resignation from the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/946486/000143774925012376/0001437749-25-012376-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.